Reuters logo
BRIEF-Beigene presents updated phase 1 data on btk inhibitor bgb-3111 in patients with chronic lymphocytic leukemia
June 14, 2017 / 10:14 AM / 5 months ago

BRIEF-Beigene presents updated phase 1 data on btk inhibitor bgb-3111 in patients with chronic lymphocytic leukemia

June 14 (Reuters) - Beigene Ltd

* Beigene presents updated phase 1 data on btk inhibitor bgb-3111 in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma at the 14th international conference on malignant lymphoma

* Beigene Ltd - ‍updated phase 1 data continue to demonstrate that bgb-3111 is well tolerated and highly active in cll/sll​

* Beigene Ltd - ‍only one patient discontinued treatment due to an ae, a grade 2 pleural effusion.​

* Beigene Ltd - ‍total of 18 serious aes (saes) occurred in 13 patients, with no sae occurring in more than one patient​

* Beigene Ltd - ‍patient with pleural effusion discontinued treatment prior to week 12 and was not evaluable for response​

* Beigene Ltd- ongoing dose-expansion component is testing doses of 160 mg twice a day (bid) or 320 mg once a day (qd). Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below